Holen Sie sich die Stockscreener-App
0.9403
7.81%
-0.0797
Handel nachbörslich:
.96
0.0197
+2.10%
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - The Malaysian Reserve
Oncolytics Biotech Inc. Price Targets Raised After ReboundJuly 2025 PreEarnings & Daily Momentum Trading Reports - newsyoung.net
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 - PR Newswire Canada
Oncolytics Biotech Announces AGM Voting Results - TipRanks
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - Eastern Progress
Live Chart Scan Detects Wedge Pattern in Oncolytics Biotech Inc.Buy Low Sell High Stock Watch Strategy in Focus - 선데이타임즈
Can Oncolytics Biotech Inc. reach all time highs this yearDaily High ROI Stock Ideas - newsyoung.net
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders - MarketScreener
Is Oncolytics Biotech Inc. a turnaround storyExtreme Return Watchlist - thegnnews.com
Oncolytics Biotech announces voting results from annual meeting By Investing.com - Investing.com Canada
Oncolytics Biotech announces voting results from annual meeting - Investing.com
RBC Capital Keeps Buy Rating on Oncolytics Biotech with $3.50 Price Target - AInvest
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Oncolytics Biotech Advances Pelareorep with Strategic Moves - MSN
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange - Eastern Progress
Oncolytics Biotech: A High-Conviction Play in the Next-Gen Immunotherapy Space - AInvest
Oncolytics Biotech to Delist from TSX, Focus on Nasdaq - The Globe and Mail
Oncolytics Biotech Reports Reduced Losses in Q2 2025 Financial Update - The Globe and Mail
(ONC) Strategic Market Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech shares fall 2.73% intraday after announcing voluntary delisting from the Toronto Stock Exchange. - AInvest
Oncolytics Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oncolytics Biotech Advances Pelareorep Clinical Program with Strategic Moves - TipRanks
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried? - The Globe and Mail
Oncolytics Biotech's Q2 Loss Narrows: A Strategic Turnaround or a Fleeting Reprieve? - AInvest
Oncolytics Reports Q2 EPS of C$0.07, C$14.6M in Cash and Cash Equivalents as of June 30, 2025. - AInvest
Oncolytics Biotech Q2 net loss narrows - MarketScreener
Oncolytics Biotech Files SEC Report Incorporating Information Circular - TipRanks
Oncolytics Biotech reports Q2 highlights, management team updates, and financial results. - AInvest
Oncolytics Biotech to delist from Toronto Stock Exchange By Investing.com - Investing.com South Africa
Oncolytics Biotech to delist from Toronto Stock Exchange - Investing.com
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - Barchart.com
Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange - Barchart.com
What to Expect From Oncolytics Biotech's Earnings - 富途牛牛
Oncolytics Biotech Inc. shares fall 1.94% after-hours as stock futures rise and trade negotiations continue. - AInvest
Oncolytics Biotech Inc. shares rise 3.16% premarket as stock futures rise ahead of tariff deadline. - AInvest
Oncolytics Biotech Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Oncolytics Biotech to Hold Virtual Annual Meeting and Announce Q2 Financial Results - TipRanks
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results - PR Newswire
Oncolytics Biotech Inc. stock momentum explainedRisk/Reward Optimization Entry Point Analysis - Newser
Bollinger Bands Show Potential Breakout in Oncolytics Biotech Inc. - beatles.ru
Published on: 2025-08-04 08:21:46 - Jammu Links News
Objective long/short (ONC) Report (ONC:CA) - news.stocktradersdaily.com
What are the latest earnings results for Oncolytics Biotech Inc.Build a diversified portfolio for steady growth - Jammu Links News
What analysts say about Oncolytics Biotech Inc. stockUnbelievable profit margins - Jammu Links News
How many analysts rate Oncolytics Biotech Inc. as a “Buy”Exceptional gains - Jammu Links News
What drives Oncolytics Biotech Inc. stock priceOutstanding growth strategies - Jammu Links News
Does Oncolytics Biotech Inc. stock perform well during market downturnsGet timely market insights for better trades - Jammu Links News
When is Oncolytics Biotech Inc. stock expected to show significant growthInvest smarter with expert stock picks - Jammu Links News
What is the risk reward ratio of investing in Oncolytics Biotech Inc. stockBuild wealth with professional market analysis - Jammu Links News
Should I hold or sell Oncolytics Biotech Inc. stock in 2025Unlock powerful trading signals for profits - Jammu Links News
Why is Oncolytics Biotech Inc. stock attracting strong analyst attentionCapitalize on stocks with high profit margins - Jammu Links News
What institutional investors are buying Oncolytics Biotech Inc. stockUnlock expert insights for smarter investing - Jammu Links News
Is it the right time to buy Oncolytics Biotech Inc. stockAchieve rapid financial growth with expert help - Jammu Links News
Is Oncolytics Biotech Inc. a growth stock or a value stockInvest smarter with real-time trading signals - Jammu Links News
What catalysts could drive Oncolytics Biotech Inc. stock higher in 2025Invest smarter with expert stock recommendations - Jammu Links News
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):